EFFCIENCY OF COMPLEX THERAPY USING ALPHA-LIPOIC ACID IN PATIENTS WITH ESSENTIAL HYPERTENSION AND TYPE 2 DIABETES DEPENDING ON GENETIC POLYMORPHISM PPAR-GAMA 2

Authors

  • Shalimova A. S. Kharkiv Medical Academy of Postgraduate Education

DOI:

https://doi.org/10.21856/j-PEP.2014.4.03

Keywords:

hypertension, type 2 diabetes, PPARγ2 polymorphism, α-lipoic acid, endothelial dysfunction

Abstract

The studies of the last years have shown that the normal tissue insulin sensitivity largely depends on functional activity of peroxisome proliferator-activating receptors. A study was conducted, the purpose of which was to evaluate the influence of genetic polymorphisms on the PPARγ2 expression of endothelial dysfunction and the effectiveness of complex therapy with the use of α-lipoic acid in patients with hypertension and type 2 diabetes. In the result of research it was found that patients with genotype Pro/Rro PPARγ2 had the more expressed hemodynamic and metabolic disorders than patients with genotype Pro12Ala / Ala12Ala. Additional appointment to patients with hypertension and the accompanying type 2 diabetes α-lipoic acid has contributed a more expressed effect on the structural and functional state of the main vessels compared to group of patients treated with only standard therapy. Decrease of glycosylated hemoglobin levels and triglycerides in patients with adding α-lipoic acid was significantly in the presence of Pro12Ala / Ala12Ala genotype.

References

Belovol AN, Shkolnik VV, Nemtsova VD. Ukrayinskiy terapevtichniy zhurnal 2012;2: 32–38.

Mayorov AYu. Saharnyj Diabet 2011;1: 35–43.

Babak OYa, Fadeenko GD, Yarmish NV, et al. Ukrayinskiy terapevtichniy zhurnal 2010;2: 12–17.

Klimenko NM. Ukrayinskiy terapevtichniy zhurnal 2010;4: 25–33.

Weimin He. PPAR Res 2009;2009: 538.

Ohshima K, Mogi M, Horiuchi M. Int J Vasc Med 2012;2012: 508416.

Mankovskiy BN. Diabet Ozhirenie Metabolicheskiy sindrom 2012;1: 31–36.

Shimamoto K. Nippon Rinso 2009;67(4): 771–776.

Colca JR, Tanis SP, McDonald WG. Kletzien Expert Opin Investig Drugs 2014;23(1): 1–7.

Chen Z, Vigueira PA, Chambers KT, et al. J Biol Chem 2012;287(28): 23537–23548.

Zhuravleva LV, Krivonosova EM. Praktikuyuchiy lIkar 2012;1: 52–58.

Heinisch B, Francesconi M, Mittermayer F, et al. Eur J Clin Invest 2010;40: 148–154.

Zhang Y, Han P, Wu N, et al. Obesity (Silver Spring) 2011;19: 1647–1653.

Ansar H, Mazloom Z, Kazemi F, et al. Saudi Med J 2011;32: 584–588.

Ying Z, Kampfrath T, Sun Q, et al. Inflamm Res 2011;60: 219–225.

Shalimova AS. Georgian Medical News 2014;4(229): 33–40.

Golbidi S, Badran M, Laher I. Diabet Ozhirenie Metabolicheskiy sindrom 2012;1: 48–58.

De Oliveira AM, Rondó PH, Luzia L A, et al. Diabetes Res Clin Pract 2011;92: 253–260.

Harrihar A, Christopher I, Jaya R, et al. The Journal of Applied Research 2005;5(4): 510–523.

Downloads

Published

2014-12-08

How to Cite

Shalimova, A. S. (2014). EFFCIENCY OF COMPLEX THERAPY USING ALPHA-LIPOIC ACID IN PATIENTS WITH ESSENTIAL HYPERTENSION AND TYPE 2 DIABETES DEPENDING ON GENETIC POLYMORPHISM PPAR-GAMA 2. Problems of Endocrine Pathology, 50(4), 26-34. https://doi.org/10.21856/j-PEP.2014.4.03

Issue

Section

CLINICAL ENDOCRINOLOGY